ClinicalTrials.gg
CompletedNCT02191397Updated Feb 25, 2020Results posted

Study to Evaluate the Efficacy, Safety and Tolerability of Bupropion Hydrochloride Extended-release Tablet, and Escitalopram Oxalate Capsule in Subjects With Major Depressive Disorder

A Phase 3 interventional study of Bupropion and Bupropion Matching Placebo in Depressive Disorder, Major, sponsored by GlaxoSmithKline. Completed at 20 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
534
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing bupropion in Depressive Disorder, Major — 1 open to participants now, 3 under way, none of them phase 3. Bupropion · Depressive Disorder, Major.

Enrollment
3rd of 37
534 · median 74
Started
2015
the only one that year
Phase 3
7 of 37
none open now
Registered
26th of 37
by date
Lead sponsor
5 of 37
GlaxoSmithKline

Among the 37 studies testing bupropion in Depressive Disorder, Major, this one is the 3rd largest by enrollment, is the only one that started in 2015, is one of 7 in phase 3, and was the 26th registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 37 studies testing bupropion in Depressive Disorder, Major is open now. Recruiting first, the newest first:

About bupropion

Bupropion: first FDA approval 1985 (WELLBUTRIN), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing bupropion in Depressive Disorder, Major, or all of them as a file.
02

Study summary

This multi-centre study will follow a randomised, double-blind, parallel-group, active-controlled design and will evaluate the efficacy, safety and tolerability of bupropion extended-release (XL) (300 mg/day) compared with escitalopram (10-20 mg/day) in outpatients and inpatients with major depressive disorder (MDD). The total duration of the study will be 11 weeks consisting of three phases. The screening phase (phase I) will be lasting for 0-14 days, subjects will be randomised to bupropion XL or escitalopram in a 1:1 ratio for acute phase treatment phase (phase II) for 8 weeks. There are 3 dose levels during this acute treatment phase. The 3-dose level plan is designed to ensure each drug is titrated according to the prescribing information and to reach an optimal clinical dose. Finally patients will enter the taper phase (phase III) for up to 1 week to assess and reduce the possible withdrawal symptoms.

In China almost all existing antidepressants are available on the market, but bupropion XL has not yet been approved. This Phase III clinical trial will be used for the purpose of registering bupropion XL in China.

03

Conditions studied

  • Depressive Disorder, Major

Keywords

  • Escitalopram
  • Major depressive disorder
  • Non-inferiority
  • Bupropion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects must have the ability to effectively communicate with investigator, complete study related documents, comprehend the key components of the consent form and must provide written to participate in the study prior to any study-specific assessments or procedures.
  • An in- patient or out-patient (male or female) and aged >=18 years.
  • A diagnosis of MDD, nonpsychotic, single episode or recurrent, -IV (DSM-IV) (296.2/296.3), utilizing the Mini International Neuropsychiatric Interview (MINI).
  • Established MDD diagnosis with a duration of at least 4 weeks.
  • HAMD-17 total score of >=20 and a CGI-S score of >=4 at both the Screening Visit and the Baseline Visit.
  • Subject must be in general good health and be considered clinically appropriate for therapy with bupropion or escitalopram, based upon the investigator's overall clinical evaluation.
  • Female patients of only: patients must not be lactating and must test negative for pregnancy at screening and agree to use a medically accepted method of during the study.
  • Liver function tests: (ALT) \<2x (ULN); alkaline phosphatase and \<=1.5xULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%).
  • (QTc) criteria: QTc \<450 milliseconds (msec) or QTc \<480msec for patients with bundle branch block. The QTc is the QT interval corrected for heart rate according to either Bazett's formula (QTcB), Fridericia's formula (QTcF), or machine or manual overread. For subject eligibility and withdrawal, QTcF will be used. For purpose of data analysis, QTcF will be used. The QTc should be based on single or averaged QTc values of triplicate (ECGs) obtained over a brief recording period.

Exclusion criteria

Exclusion Criteria:

  • Has been diagnosed or received treatment for a primary Axis I disorder with the exception of MDD (including current or past diagnosis of anorexia nervosa or bulimia). Additionally, subjects diagnosed with dysthymic disorder within the past 2 years will be excluded.
  • Current Axis II diagnosis that suggests non-compliance with the protocol.
  • A subject who, in the assessment with the Columbia Suicide Severity Rating Scale (C-SSRS) and investigator's judgment, poses suicidal risk, or had suicide attempt or behavior within 6 months prior to the Screening Visit.
  • Current or past history of seizure disorder or brain injury (traumatic or disease related); or any condition which, in the opinion of the investigator, predisposed to seizure; subjects treated with other medications or treatment regimes that lower seizure threshold. Note: single childhood febrile seizure is not exclusionary.
  • In the Investigator's judgment, presence of laboratory test results (including , hematology, chemistry and urine), or the conditions which render patients unsuitable for the study (such as serious cardiovascular disease, uncontrolled hypertension, liver or renal insufficiency) and pose a safety concern or interfere with the accurate safety and efficacy assessments. Subjects with co-morbidities (such as diabetes, hypertension, hypothyroid, chronic respiratory diseases or other physical illness) were eligible if their condition had been stable for at least three months and they had been receiving standard therapy for the condition for at least three months.
  • Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Frequent and/or severe allergic reactions with multiple medications, or history of a medically significant adverse effect (including allergic reaction) from any medications or compounds in the study.
  • Use of prohibited psychotropic drugs not allowed within seven days (14 days for monoamine oxidase inhibitors (MAOIs), 30 days for fluoxetine) prior to the Baseline Visit.
  • Subjects who have attended any studies investigating bupropion or escitalopram 6 months prior to this study, or use of bupropion or escitalopram in the last 4 weeks.
  • Participation in other clinical studies unrelated to the current illness within 30 days or participation in other clinical studies related to the current illness within 3 months.
  • Initiation of systematic psychotherapy within three months prior to the Screening Visit, or plans to initiate systematic psychotherapy during the study.
  • Received electroconvulsive therapy (ECT), modify electroconvulsive therapy (MECT), transcranial magnetic stimulation (TMS), or other physical therapy within the 6 months prior to the Screening Visit.
  • Previous failure of bupropion or escitalopram treatment with adequate courses and doses.
  • Previous or present failure of two different classes of antidepressants treatment with adequate courses (e.g. maximum labelled doses for >=4 weeks).
  • History of substance abuse (alcohol or drugs) or substance dependence within 12 months (as defined in the DSM-IV).
  • Other conditions which, in the Investigator's judgment, render patients unsuitable for the clinical study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
534 participants (actual)

Study arms

  • Experimental
    Bupropion Treatment Arm

    Subject will receive bupropion in 3 dose levels along with escitalopram matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive bupropion XL 150 milligram (mg) per day for a week. At dose level 2 (Week 1 to Week 4), bupropion XL dose will be increased to 300mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), bupropion XL dose will be maintained at 300mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of bupropion XL will be reduced to 150mg/day for 1 week before discontinuation.

    Drug: Bupropion · Drug: Escitalopram Matching Placebo

  • Active comparator
    Escitalopram Treatment Arm

    Subject will receive escitalopram in 3 dose levels along with bupropion matching placebo to maintain the blind in acute treatment phase. At dose level 1 (Week 0 to Week 1), Subjects will receive escitalopram 10mg/day for a week. At dose level 2 (Week 1 to Week 4), escitalopram dose will be maintained at 10mg/day for further 3 weeks. At dose level 3 (Week 4 to Week 8), escitalopram dose will be increased to 20mg/day. Subjects intolerable to dose level 3 will be allowed to down titrate to dose level 2 at anytime, and maintain the dose until the end of acute treatment phase (Week 8, Visit 7). At the end of acute treatment phase, the dose of escitalopram 20mg/day, the dose will be reduced to 10 mg/day for 1 week before discontinuation, while those receiving 10mg/day will discontinuation directly.

    Drug: Bupropion Matching Placebo · Drug: Escitalopram

Interventions

  • Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.

  • DrugBupropion Matching Placebo

    Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding

  • Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.

  • DrugEscitalopram Matching Placebo

    Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding

06

What researchers measure

Primary outcomes

  1. Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)

    HAMD-17 is used to assess the severity of depression and symptom improvement. It consisted of 17 questions. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Change from Baseline was calculated by subtracting the Baseline total score (at Day 0, Week 0) from Week 8 observed total score. The Per Protocol (PP) Population is defined as all randomized participants in the Intent-To-Treat (ITT) Population who do not meet criteria of a major protocol deviation, with overall compliance of active drug for acute treatment phase in the range of 75%-125% and complete the first 6 weeks treatment and has HAMD-17 assessment at/after week 6 (that is \>=35 days). All participants in the PP population were included in the mixed model repeated measures analysis. Only those participants with data available at the specified time point were analyzed.

    Time frame: Baseline (Week 0) and Week 8

Secondary outcomes

  1. Response Rate Based on HAMD-17 Total Score

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Response was defined as decrease in HAMD-17 total scores at end of acute treatment phase (Week 8) relative to Baseline by at least 50%. Non-responder Imputation was used in calculation of rates.

    Time frame: Up to Week 8

  2. Remission Rate Based on HAMD-17 Total Score

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Remission was defined as HAMD-17 total scores at end of acute treatment phase (Week 8) \<=7.

    Time frame: Up to Week 8

  3. Sustained Response Rate Based on HAMD-17 Total Score

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained response was defined as response at end of acute treatment phase and an earlier visit and the decrease from Baseline in non-missing HAMD-17 total scores at all visits between these two visits by at least 40%.

    Time frame: Up to Week 8

  4. Sustained Remission Rate Based on HAMD-17 Total Score

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained remission was defined as remission at end of acute treatment phase and an earlier visit and non-missing HAMD-17 total scores at all visits between these two visits \<=8.

    Time frame: Up to Week 8

  5. Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 1, 2, 4, 6 and 8

    MADRS is a 10-point rating scale. Each item is scored on a scale of 0-6, with a total score range of 0-60. Higher score indicates worst symptoms. This scale is mainly used to assess the efficacy of antidepressant treatment. The ratings were based on the signs and symptoms during the preceding week prior to the visit. Values at Day0, Week 0 was considered as Baseline value. The observed MADRS total score was considered as missing if any item is missing. Change from Baseline in MADRS was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  6. Change From Baseline in HAMD-17 Depressed Mood Subscale Score (Score of Item 1) at Weeks 1, 2, 4, 6 and 8

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Depressed Mood Subscale is a factor score of item-1 (Depressed Mood) of HAMD-17 scale. This subscale has a score in a range of 0 (absence of depressed mood feelings) to 4 (when participants report virtually only these feeling states in his/her spontaneous verbal and non-verbal communicationtotal score). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  7. Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score (Sum of Scores of Items 10, 11, 12, 13, 15 and 17) at Weeks 1, 2, 4, 6 and 8

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Anxiety/Somatization subscale score was derived as sum of scores of items 10, 11, 12, 13, 15 and 17 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 18 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  8. Change From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Retardation subscale score was derived as sum of scores of items 1, 7, 8 and 14 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 14 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  9. Change From Baseline in HAMD-17 Sleep Disorder Subscale Score (Sum of Scores of Items 4, 5 and 6) at Weeks 1, 2, 4, 6 and 8

    HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Sleep Disorder subscale score was derived as sum of scores of items 4, 5 and 6 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 6 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  10. Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Weeks 1, 2, 4, 6 and 8

    CGI-S records the severity of illness at specific time points, with a range of responses from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Participants with zero values (0) representing "Not assessed" were excluded from analysis. Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  11. Percentage of Participants With a Clinical Global Impression Global Improvement (CGI-I) Score of 1 ("Very Much Improved") or 2 ("Much Improved") at Weeks 1, 2, 4, 6 and 8

    For CGI-I rating, the raters indicated their assessment of the participant's total improvement or worsening compared to the participant's condition at the Baseline visit, whether or not the improvement or worsening was thought to be treatment related. Scores ranges from 0 to 7 where 0 represents "Not assessed", and the remaining values 1-7 represent "Very much improved" (1) to "Very much worse" (7). Participants with score 0 were excluded from analysis. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

    Time frame: Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8

  12. Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious AE (SAE)

    An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants who received any of the study treatment and had any non-serious AE or SAE were considered for analysis. Safety Population comprised of all participants who took at least one dose of the study medication.

    Time frame: Up to Week 10

  13. Change From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  14. Change From Baseline in Hematocrit at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  15. Change From Baseline in White Blood Cell (WBC) Count, Total Neutrophil, Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  16. Change From Baseline in Total Bilirubin, Direct Bilirubin and Creatinine at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  17. Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT) and Lactose Dehydrogenase (LD) at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  18. Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  19. Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  20. Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  21. Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points

    Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  22. Number of Participants With Urinalysis Data Outside the Normal Range

    Urine samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Number of participants with urine specific gravity and potential of hydrogen (pH) outside (higher or lower) the normal range are presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Week 10

  23. Number of Participants With Vital Sign Parameters Outside the Clinical Concern Range

    Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were taken at Screening (within 14 days prior to dosing), randomization visit (Week 0) and at Weeks 1, 2, 4, 6, 8, Taper visit (Week 9) and Follow-up visit (Week 10). SBP \<30 or \>170 millimeter of mercury (mmHg); DBP \<20 or \>110 mmHg and heart rate \<40 or \>120 beats per minute (bpm) were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with vital signs outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.

    Time frame: Up to Week 10

  24. Number of Participants With Electrocardiogram (ECG) Data Outside the Clinical Concern Range

    ECG was recorded at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). PR interval \<110 or \>220 millisecond (msec); QRS interval \<60 or \>120 msec and corrected QT (QTc) interval \>450 msec were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with ECG data outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.

    Time frame: Up to Week 10

  25. Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ)

    CSFQ is a questionnaire about sexual activity and sexual function (sexual intercourse, masturbation, sexual fantasies and other activity). CSFQ is a gender-specific questionnaire. Both male and female versions consist of 14 items, each with 5 possible answers. CSFQ has a score in a range of 14 to 70. Higher score indicates higher sexual activity and sexual function. Value at Day 0 (Week 0) was considered as Baseline value. Change from Baseline at Week 8 was calculated by subtracting the Baseline score from the specific post-Baseline score. Only those participants with data available at the specified time points were analyzed.

    Time frame: Baseline (Day 0) and Week 8

  26. Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. It consists of 10 items, each with two possible answers (yes/no). Suicidal ideation was interpreted if "yes" answer at any time during treatment to any one of the five suicidal ideation questions (item 1-5) on the C-SSRS. Suicidal behavior was interpreted if a "yes" answer at any time during treatment to any one of the five suicidal behavior questions (item 6-10) on the C-SSRS. Suicidal ideation or behavior is interpreted if a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (item 1-10) on the C-SSRS. Number of participants with at least one on-treatment C-SSRS assessment were analyzed. Only those participants with data available at the specified time points were analyzed.

    Time frame: Baseline and up to Taper visit (Week 9)

07

Results

Posted Feb 18, 2019

Participant flow

This was a multi-center, randomized, double-blind, parallel active-controlled study to evaluate the efficacy, safety and tolerability of bupropion hydrochloride extended-release (XL) and escitalopram oxalate in participants with major depressive disorder. This study was conducted in China from 10-February-2015 to 25-October-2016.

Participant flow — Overall Study
MilestoneBupropion XLEscitalopram
Started266268
Completed183198
Not completed8370
Withdrew: Adverse event2817
Withdrew: Lack of efficacy105
Withdrew: Protocol violation03
Withdrew: Met protocol-defined stopping criteria54
Withdrew: Lost to follow-up1011
Withdrew: Physician decision83
Withdrew: Withdrawal by subject2227

Outcome measures

PrimaryMean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)

HAMD-17 is used to assess the severity of depression and symptom improvement. It consisted of 17 questions. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Change from Baseline was calculated by subtracting the Baseline total score (at Day 0, Week 0) from Week 8 observed total score. The Per Protocol (PP) Population is defined as all randomized participants in the Intent-To-Treat (ITT) Population who do not meet criteria of a major protocol deviation, with overall compliance of active drug for acute treatment phase in the range of 75%-125% and complete the first 6 weeks treatment and has HAMD-17 assessment at/after week 6 (that is \>=35 days). All participants in the PP population were included in the mixed model repeated measures analysis. Only those participants with data available at the specified time point were analyzed.

Time frame:
Baseline (Week 0) and Week 8
Reported as:
Least squares mean · Scores on a scale
Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)
Scores on a scaleBupropion XLEscitalopram
Mean Change in Hamilton Depression Rating Scale - 17 (HAMD-17) Total Score From Baseline to End of Acute Treatment Phase (Week 8)-14.5 ± 0.41-15.4 ± 0.39
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.139 (Analysis included Baseline HAMD-17 total score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.8 · 95% CI -0.27 to 1.94Observed Cases (OC) dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryResponse Rate Based on HAMD-17 Total Score

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Response was defined as decrease in HAMD-17 total scores at end of acute treatment phase (Week 8) relative to Baseline by at least 50%. Non-responder Imputation was used in calculation of rates.

Time frame:
Up to Week 8
Reported as:
Number · Percentage of Participants
Response Rate Based on HAMD-17 Total Score
Percentage of ParticipantsBupropion XLEscitalopram
Response Rate Based on HAMD-17 Total Score69.672.9
Statistical analysis
  • Bupropion XL vs Escitalopram · GEE model · p = 0.479 (P-value was estimated from a Generalized Estimating Equation (GEE) model with Response based on HADM-17 as response variable and treatment, gender as explanatory variables.) · Odds ratio (or): 0.85 · 95% CI 0.55 to 1.33
SecondaryRemission Rate Based on HAMD-17 Total Score

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Remission was defined as HAMD-17 total scores at end of acute treatment phase (Week 8) \<=7.

Time frame:
Up to Week 8
Reported as:
Number · Percentage of Participants
Remission Rate Based on HAMD-17 Total Score
Percentage of ParticipantsBupropion XLEscitalopram
Remission Rate Based on HAMD-17 Total Score39.747.2
Statistical analysis
  • Bupropion XL vs Escitalopram · GEE model · p = 0.129 (P-value was estimated from a Generalized Estimating Equation (GEE) model with Response based on HADM-17 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.73 · 95% CI 0.48 to 1.10
SecondarySustained Response Rate Based on HAMD-17 Total Score

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained response was defined as response at end of acute treatment phase and an earlier visit and the decrease from Baseline in non-missing HAMD-17 total scores at all visits between these two visits by at least 40%.

Time frame:
Up to Week 8
Reported as:
Number · Percentage of Participants
Sustained Response Rate Based on HAMD-17 Total Score
Percentage of ParticipantsBupropion XLEscitalopram
Sustained Response Rate Based on HAMD-17 Total Score51.656.3
Statistical analysis
  • Bupropion XL vs Escitalopram · GEE model · p = 0.354 (P-value was estimated from a GEE model with Response based on HADM-17 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.83 · 95% CI 0.55 to 1.24
SecondarySustained Remission Rate Based on HAMD-17 Total Score

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 total score is calculated by summing the individual response scores if there is no missing response. HAMD-17 has a total score in a range of 0 (not present) to 52 (severe). Values at Day 0, Week 0 was considered as Baseline value. Sustained remission was defined as remission at end of acute treatment phase and an earlier visit and non-missing HAMD-17 total scores at all visits between these two visits \<=8.

Time frame:
Up to Week 8
Reported as:
Number · Percentage of Participants
Sustained Remission Rate Based on HAMD-17 Total Score
Percentage of ParticipantsBupropion XLEscitalopram
Sustained Remission Rate Based on HAMD-17 Total Score25.528.6
Statistical analysis
  • Bupropion XL vs Escitalopram · GEE model · p = 0.489 (P-value was estimated from a GEE model with Response based on HADM-17 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.85 · 95% CI 0.54 to 1.34
SecondaryChange From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 1, 2, 4, 6 and 8

MADRS is a 10-point rating scale. Each item is scored on a scale of 0-6, with a total score range of 0-60. Higher score indicates worst symptoms. This scale is mainly used to assess the efficacy of antidepressant treatment. The ratings were based on the signs and symptoms during the preceding week prior to the visit. Values at Day0, Week 0 was considered as Baseline value. The observed MADRS total score was considered as missing if any item is missing. Change from Baseline in MADRS was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Weeks 1, 2, 4, 6 and 8
Scores on a scaleBupropion XLEscitalopram
Week 1, n=184, 199-3.6 ± 0.34-3.8 ± 0.33
Week 2, n=182, 199-7.0 ± 0.47-8.3 ± 0.45
Week 4, n=184, 198-11.2 ± 0.58-12.4 ± 0.56
Week 6, n=183, 196-15.5 ± 0.59-16.3 ± 0.57
Week 8, n=176, 188-18.6 ± 0.57-19.5 ± 0.55
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.627 (Analysis included Baseline MADRS total score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.70 to 1.16Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.037 (Analysis included Baseline MADRS total score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 1.4 · 95% CI 0.08 to 2.66Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.143 (Analysis included Baseline MADRS total score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 1.2 · 95% CI -0.40 to 2.78Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.330 (Analysis included Baseline MADRS total score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.8 · 95% CI -0.81 to 2.40Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.278 (Analysis included Baseline MADRS total score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.9 · 95% CI -0.69 to 2.40Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryChange From Baseline in HAMD-17 Depressed Mood Subscale Score (Score of Item 1) at Weeks 1, 2, 4, 6 and 8

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Depressed Mood Subscale is a factor score of item-1 (Depressed Mood) of HAMD-17 scale. This subscale has a score in a range of 0 (absence of depressed mood feelings) to 4 (when participants report virtually only these feeling states in his/her spontaneous verbal and non-verbal communicationtotal score). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in HAMD-17 Depressed Mood Subscale Score (Score of Item 1) at Weeks 1, 2, 4, 6 and 8
Scores on a scaleBupropion XLEscitalopram
Week 1, n=184, 199-0.4 ± 0.04-0.4 ± 0.04
Week 2, n=182, 199-0.7 ± 0.06-0.8 ± 0.05
Week 4, n=184, 198-1.1 ± 0.06-1.3 ± 0.06
Week 6, n=183, 197-1.5 ± 0.06-1.6 ± 0.06
Week 8, n=176, 188-1.9 ± 0.06-1.9 ± 0.06
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.579 (Analysis included Baseline HAMD-17 depressed mood subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.0 · 95% CI -0.09 to 0.16Comparison for Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.163 (Analysis included Baseline HAMD-17 depressed mood subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.1 · 95% CI -0.04 to 0.26Comparison for Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.050 (Analysis included Baseline HAMD-17 depressed mood subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI 0.00 to 0.34Comparison for Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.337 (Analysis included Baseline HAMD-17 depressed mood subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.1 · 95% CI -0.09 to 0.26Comparison for Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.714 (Analysis included Baseline HAMD-17 depressed mood subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.0 · 95% CI -0.14 to 0.20Comparison for Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryChange From Baseline in HAMD-17 Anxiety/Somatization Subscale Score (Sum of Scores of Items 10, 11, 12, 13, 15 and 17) at Weeks 1, 2, 4, 6 and 8

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Anxiety/Somatization subscale score was derived as sum of scores of items 10, 11, 12, 13, 15 and 17 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 18 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in HAMD-17 Anxiety/Somatization Subscale Score (Sum of Scores of Items 10, 11, 12, 13, 15 and 17) at Weeks 1, 2, 4, 6 and 8
Scores on a scaleBupropion XLEscitalopram
Week 1, n=184, 199-1.3 ± 0.12-1.1 ± 0.12
Week 2, n=182, 199-2.0 ± 0.15-2.4 ± 0.14
Week 4, n=184, 198-3.0 ± 0.19-3.4 ± 0.18
Week 6, n=183, 197-4.0 ± 0.17-4.4 ± 0.17
Week 8, n=176, 188-4.8 ± 0.16-5.1 ± 0.16
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.358 (Analysis included Baseline HAMD-17 anxiety/somatization subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): -0.2 · 95% CI -0.50 to 0.18Comparison for Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.081 (Analysis included Baseline HAMD-17 anxiety/somatization subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.4 · 95% CI -0.04 to 0.75Comparison for Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.062 (Analysis included Baseline HAMD-17 anxiety/somatization subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.5 · 95% CI -0.02 to 0.99Comparison for Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.118 (Analysis included Baseline HAMD-17 anxiety/somatization subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.4 · 95% CI -0.10 to 0.85Comparison for Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.252 (Analysis included Baseline HAMD-17 anxiety/somatization subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.3 · 95% CI -0.19 to 0.71Comparison for Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryChange From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Retardation subscale score was derived as sum of scores of items 1, 7, 8 and 14 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 14 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in HAMD-17 Retardation Subscale Score (Sum of Scores of Items 1, 7, 8 and 14) at Weeks 1, 2, 4, 6 and 8
Scores on a scaleBupropion XLEscitalopram
Week 1, n=184, 199-1.0 ± 0.10-1.0 ± 0.10
Week 2, n=182, 199-1.8 ± 0.13-2.0 ± 0.13
Week 4, n=184, 198-2.9 ± 0.15-3.1 ± 0.15
Week 6, n=183, 197-3.9 ± 0.16-3.9 ± 0.16
Week 8, n=176, 188-4.7 ± 0.17-4.9 ± 0.16
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.573 (Analysis included Baseline HAMD-17 Retardation subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.1 · 95% CI -0.20 to 0.35Comparison for Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.209 (Analysis included Baseline HAMD-17 Retardation subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.13 to 0.58Comparison for Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.427 (Analysis included Baseline HAMD-17 Retardation subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.25 to 0.58Comparison for Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.851 (Analysis included Baseline HAMD-17 Retardation subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.0 · 95% CI -0.40 to 0.48Comparison for Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.370 (Analysis included Baseline HAMD-17 Retardation subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.25 to 0.66Comparison for Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryChange From Baseline in HAMD-17 Sleep Disorder Subscale Score (Sum of Scores of Items 4, 5 and 6) at Weeks 1, 2, 4, 6 and 8

HAMD-17 is an extensively used tool to assess the severity of depression and symptom improvement during the treatment. The HAMD-17 adopted for this study consisted of 17 questions with multiple choice responses, each of which is numerically scored. The HAMD-17 Sleep Disorder subscale score was derived as sum of scores of items 4, 5 and 6 from HAMD-17. This subscale has a score in a range of 0 (absence of condition) to 6 (most severe condition). Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was calculated by subtracting the Baseline response from the specific post-Baseline response. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in HAMD-17 Sleep Disorder Subscale Score (Sum of Scores of Items 4, 5 and 6) at Weeks 1, 2, 4, 6 and 8
Scores on a scaleBupropion XLEscitalopram
Week 1, n=184, 199-0.6 ± 0.10-0.7 ± 0.09
Week 2, n=182, 199-0.8 ± 0.11-1.2 ± 0.10
Week 4, n=184, 198-1.4 ± 0.11-1.6 ± 0.11
Week 6, n=183, 197-1.8 ± 0.11-2.0 ± 0.11
Week 8, n=176, 188-2.3 ± 0.11-2.4 ± 0.11
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.438 (Analysis included Baseline HAMD-17 Sleep Disorder subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.1 · 95% CI -0.16 to 0.37Comparison for Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.014 (Analysis included Baseline HAMD-17 Sleep Disorder subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.4 · 95% CI 0.07 to 0.66Comparison for Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.207 (Analysis included Baseline HAMD-17 Sleep Disorder subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.11 to 0.50Comparison for Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.137 (Analysis included Baseline HAMD-17 Sleep Disorder subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.07 to 0.54Comparison for Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.299 (Analysis included Baseline HAMD-17 Sleep Disorder subscale score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.14 to 0.46Comparison for Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryChange From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Weeks 1, 2, 4, 6 and 8

CGI-S records the severity of illness at specific time points, with a range of responses from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Participants with zero values (0) representing "Not assessed" were excluded from analysis. Values at Day 0, Week 0 was considered as Baseline value. Change from Baseline was obtained by subtracting the Baseline value from the specific post-Baseline value. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · Scores on a scale
Change From Baseline in Clinical Global Impression-Severity of Illness Scale (CGI-S) Score at Weeks 1, 2, 4, 6 and 8
Scores on a scaleBupropion XLEscitalopram
Week 1, n=184, 199-0.3 ± 0.04-0.4 ± 0.04
Week 2, n=182, 199-0.7 ± 0.05-0.8 ± 0.05
Week 4, n=184, 198-1.1 ± 0.07-1.3 ± 0.06
Week 6, n=183, 197-1.6 ± 0.07-1.7 ± 0.07
Week 8, n=176, 188-2.1 ± 0.07-2.2 ± 0.07
Statistical analysis
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.804 (Analysis included Baseline CGI-S score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.0 · 95% CI -0.10 to 0.13Comparison for Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.079 (Analysis included Baseline CGI-S score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.1 · 95% CI -0.02 to 0.28Comparison for Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.036 (Analysis included Baseline CGI-S score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI 0.01 to 0.38Comparison for Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.248 (Analysis included Baseline CGI-S score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.1 · 95% CI -0.08 to 0.31Comparison for Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · Mixed model repeated measures analysis · p = 0.110 (Analysis included Baseline CGI-S score as covariate, treatment, gender, visit and treatment-visit interaction as fixed effects. Unstructured covariance matrix was used.) · Mean difference (final values): 0.2 · 95% CI -0.04 to 0.35Comparison for Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryPercentage of Participants With a Clinical Global Impression Global Improvement (CGI-I) Score of 1 ("Very Much Improved") or 2 ("Much Improved") at Weeks 1, 2, 4, 6 and 8

For CGI-I rating, the raters indicated their assessment of the participant's total improvement or worsening compared to the participant's condition at the Baseline visit, whether or not the improvement or worsening was thought to be treatment related. Scores ranges from 0 to 7 where 0 represents "Not assessed", and the remaining values 1-7 represent "Very much improved" (1) to "Very much worse" (7). Participants with score 0 were excluded from analysis. All participants in the PP population were analyzed and n=X in the category titles represented the number of participants with data available at the specified time points.

Time frame:
Baseline (Week 0) and Weeks 1, 2, 4, 6 and 8
Reported as:
Number · Percentage of Participants
Percentage of Participants With a Clinical Global Impression Global Improvement (CGI-I) Score of 1 ("Very Much Improved") or 2 ("Much Improved") at Weeks 1, 2, 4, 6 and 8
Percentage of ParticipantsBupropion XLEscitalopram
Week 1, n=184, 19967.5
Week 2, n=182, 19921.422.1
Week 4, n=184, 19838.652.5
Week 6, n=183, 19767.871.6
Week 8, n=176, 18880.783.5
Statistical analysis
  • Bupropion XL vs Escitalopram · GEE model repeated measures · p = 0.545 (P-value was estimated from a GEE model repeated measures with CGI-I score of 1 or 2 as response variable and treatment, gender as explanatory variables) · Odds ratio, log: 0.78 · 95% CI 0.35 to 1.75Comparison for Week 1. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · GEE model repeated measures · p = 0.822 (P-value was estimated from a GEE model repeated measures with CGI-I score of 1 or 2 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.95 · 95% CI 0.58 to 1.54Comparison for Week 2. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · GEE model repeated measures · p = 0.007 (P-value was estimated from a GEE model repeated measures with CGI-I score of 1 or 2 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.57 · 95% CI 0.38 to 0.86Comparison for Week 4. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · GEE model repeated measures · p = 0.417 (P-value was estimated from a GEE model repeated measures with CGI-I score of 1 or 2 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.83 · 95% CI 0.54 to 1.29Comparison for Week 6. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
  • Bupropion XL vs Escitalopram · GEE model repeated measures · p = 0.485 (P-value was estimated from a GEE model repeated measures with CGI-I score of 1 or 2 as response variable and treatment, gender as explanatory variables) · Odds ratio (or): 0.83 · 95% CI 0.49 to 1.40Comparison for Week 8. OC dataset was used, where available data at a given time point was used with no missing values filled in with estimates.
SecondaryNumber of Participants With Any Non-serious Adverse Event (AE) and Any Serious AE (SAE)

An AE is any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or all events of possible drug-induced liver injury with hyperbilirubinemia were categorized as SAE. Participants who received any of the study treatment and had any non-serious AE or SAE were considered for analysis. Safety Population comprised of all participants who took at least one dose of the study medication.

Time frame:
Up to Week 10
Reported as:
Count of participants · Participants
Number of Participants With Any Non-serious Adverse Event (AE) and Any Serious AE (SAE)
ParticipantsBupropion XLEscitalopram
Any non-serious AE151150
Any SAE1011
SecondaryChange From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Gram per Liter (G/L)
Change From Baseline in Hemoglobin, Total Protein, Albumin and Mean Corpuscle Hemoglobin Concentration (MCHC) at the Indicated Time Points
Gram per Liter (G/L)Bupropion XLEscitalopram
Hemoglobin, Week 8, n=176, 183-0.22 ± 7.621-1.16 ± 7.874
Hemoglobin, Taper, n=13, 16-1.54 ± 5.8681.38 ± 8.057
Hemoglobin, Follow-up, n=10, 8-3.10 ± 12.4490.38 ± 6.163
Total protein, Week 8, n=174, 183-0.640 ± 5.2784-0.891 ± 4.0339
Total protein, Taper, n=12, 151.197 ± 6.93472.000 ± 8.7513
Total protein, Follow-up, n=8, 12-4.650 ± 5.5131-1.227 ± 4.8619
Albumin, Week 8, n=175, 183-0.254 ± 3.0207-0.678 ± 2.8483
Albumin, Taper, n=12, 15-0.086 ± 3.9688-0.027 ± 4.2372
Albumin, Follow-up, n=8, 12-1.925 ± 2.0084-1.577 ± 3.6313
MCHC, Week 8, n=176, 183-0.09 ± 8.9330.76 ± 9.821
MCHC, Taper, n=13, 160.54 ± 8.8282.25 ± 9.030
MCHC, Follow-up, n=10, 8-2.10 ± 9.398-2.88 ± 5.055
SecondaryChange From Baseline in Hematocrit at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit at the Indicated Time Points
Proportion of red blood cells in bloodBupropion XLEscitalopram
Hematocrit, Week 8, n=176, 1830.0016 ± 0.06088-0.0044 ± 0.02587
Hematocrit, Taper, n=13, 16-0.0051 ± 0.021050.0017 ± 0.02601
Hematocrit, Follow-up, n=10, 8-0.0076 ± 0.044030.0051 ± 0.01509
SecondaryChange From Baseline in White Blood Cell (WBC) Count, Total Neutrophil, Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Giga cells per liter (GI/L)
Change From Baseline in White Blood Cell (WBC) Count, Total Neutrophil, Lymphocyte, Basophil, Eosinophil, Monocyte and Platelet Count at the Indicated Time Points
Giga cells per liter (GI/L)Bupropion XLEscitalopram
WBC count, Week 8, n=176, 183-0.032 ± 1.6278-0.073 ± 1.6282
WBC count, Taper, n=13, 160.065 ± 1.5513-0.715 ± 1.8547
WBC count, Follow-up, n=10, 8-0.743 ± 1.44550.427 ± 0.9032
Total Neutrophils, Week 8, n=176, 1830.101 ± 1.4835-0.165 ± 1.5540
Total Neutrophils, Taper, n=13, 160.306 ± 1.6222-0.772 ± 1.5656
Total Neutrophils, Follow-up, n=10, 8-0.869 ± 1.45780.424 ± 0.7470
Lymphocytes, Week 8, n=176, 183-0.154 ± 0.48330.072 ± 0.4190
Lymphocytes, Taper, n=13, 16-0.242 ± 0.48430.077 ± 0.5053
Lymphocytes, Follow-up, n=10, 80.042 ± 0.39370.022 ± 0.4388
Basophil, Week 8, n=176, 1820.001 ± 0.01730.002 ± 0.0218
Basophil, Taper, n=13, 160.001 ± 0.00910.001 ± 0.0131
Basophil, Follow-up, n=10, 8-0.003 ± 0.0163-0.012 ± 0.0087
Eosinophil, Week 8, n=176, 182-0.004 ± 0.07880.010 ± 0.0899
Eosinophil, Taper, n=13, 16-0.012 ± 0.05920.006 ± 0.0488
Eosinophil, Follow-up, n=10, 8-0.005 ± 0.06270.019 ± 0.0813
Monocyte, Week 8, n=176, 1820.021 ± 0.11800.003 ± 0.1113
Monocyte, Taper, n=13, 16-0.001 ± 0.1023-0.031 ± 0.0917
Monocyte, Follow-up, n=10, 80.058 ± 0.12920.010 ± 0.0920
Platelet count, Week 8, n=176, 1837.73 ± 32.7250.56 ± 29.492
Platelet count, Taper, n=13, 1617.15 ± 35.1267.19 ± 22.448
Platelet count, Follow-up, n=10, 828.50 ± 35.6005.38 ± 24.784
SecondaryChange From Baseline in Total Bilirubin, Direct Bilirubin and Creatinine at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Micromoles per liter (µmol/L)
Change From Baseline in Total Bilirubin, Direct Bilirubin and Creatinine at the Indicated Time Points
Micromoles per liter (µmol/L)Bupropion XLEscitalopram
Total bilirubin, Week 8, n=175, 181-0.812 ± 4.7591-0.071 ± 4.8022
Total bilirubin, Taper, n=12, 15-3.457 ± 6.55211.198 ± 3.9442
Total bilirubin, Follow-up, n=8, 120.382 ± 4.01510.338 ± 3.4710
Direct bilirubin, Week 8, n=175, 180-0.072 ± 1.3659-0.006 ± 1.2310
Direct bilirubin, Taper, n=11, 15-1.554 ± 3.76070.654 ± 1.7145
Direct bilirubin, Follow-up, n=8, 12-0.102 ± 1.11920.382 ± 0.9070
Creatinine, Week 8, n=174, 1837.507 ± 10.68520.307 ± 9.0811
Creatinine, Taper, n=12, 156.675 ± 6.91340.880 ± 10.3281
Creatinine, Follow-up, n=8, 114.237 ± 8.92911.618 ± 9.6668
SecondaryChange From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT) and Lactose Dehydrogenase (LD) at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · International Units per liter (IU/L)
Change From Baseline in Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-glutamyl Transpeptidase (GGT) and Lactose Dehydrogenase (LD) at the Indicated Time Points
International Units per liter (IU/L)Bupropion XLEscitalopram
ALT, Week 8, n=176, 1832.254 ± 14.72081.315 ± 10.3019
ALT, Taper, n=12, 167.993 ± 17.5985-1.812 ± 15.1544
ALT, Follow-up, n=8, 12-7.337 ± 21.78095.938 ± 19.8234
ALP, Week 8, n=176, 1811.866 ± 13.27760.407 ± 11.7870
ALP, Taper, n=12, 153.674 ± 11.58033.480 ± 19.2823
ALP, Follow-up, n=7, 125.643 ± 9.2858-3.953 ± 11.6377
AST, Week 8, n=176, 1830.330 ± 7.62591.099 ± 6.1029
AST, Taper, n=12, 163.193 ± 7.49900.381 ± 6.0938
AST, Follow-up, n=8, 120.925 ± 23.34852.867 ± 11.0264
GGT, Week 8, n=175, 1810.688 ± 17.0699-0.694 ± 11.1878
GGT, Taper, n=12, 151.403 ± 6.2977-3.133 ± 4.8019
GGT, Follow-up, n=7, 12-2.029 ± 5.96373.916 ± 25.9888
LD, Week 8, n=176, 1821.292 ± 32.46272.879 ± 27.3838
LD, Taper, n=13, 1314.463 ± 28.9571-8.092 ± 55.0095
LD, Follow-up, n=8, 1011.037 ± 45.3316-4.150 ± 33.8871
SecondaryChange From Baseline in Calcium, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Millimole per liter (mmol/L)
Change From Baseline in Calcium, Chloride, Cholesterol, Glucose, Potassium, Sodium, Triglyceride and Urea at the Indicated Time Points
Millimole per liter (mmol/L)Bupropion XLEscitalopram
Calcium, Week 8, n=173, 183-0.017 ± 0.1139-0.020 ± 0.1225
Calcium, Taper, n=12, 12-0.019 ± 0.19060.012 ± 0.1091
Calcium, Follow-up, n=8, 11-0.060 ± 0.1032-0.060 ± 0.1352
Chloride, Week 8, n=173, 1820.259 ± 2.7943-0.293 ± 2.5913
Chloride, Taper, n=10, 13-0.498 ± 3.2001-0.566 ± 2.4684
Chloride, Follow-up, n=8, 8-0.287 ± 3.6588-0.178 ± 4.6453
Cholesterol, Week 8, n=175, 181-0.122 ± 0.58550.051 ± 0.5931
Cholesterol, Taper, n=12, 140.022 ± 0.58910.082 ± 0.5991
Cholesterol, Follow-up, n=9, 11-0.124 ± 0.5149-0.122 ± 0.5899
Glucose, Week 8, n=173, 181-0.051 ± 0.6327-0.050 ± 0.5871
Glucose, Taper, n=12, 160.352 ± 0.38220.106 ± 0.9661
Glucose, Follow-up, n=9, 11-0.194 ± 0.40890.025 ± 1.2117
Potassium, Week 8, n=173, 182-0.021 ± 0.35040.009 ± 0.3552
Potassium, Taper, n=10, 13-0.114 ± 0.41650.046 ± 0.5095
Potassium, Follow-up, n=8, 8-0.110 ± 0.62210.036 ± 0.6556
Sodium, Week 8, n=173, 182-0.205 ± 2.4757-0.178 ± 2.5481
Sodium, Taper, n=10, 13-0.611 ± 3.07990.978 ± 1.5853
Sodium, Follow-up, n=8, 8-0.175 ± 3.90850.770 ± 3.6011
Triglycerides, Week 8, n=175, 1810.003 ± 1.04990.022 ± 0.5844
Triglycerides, Taper, n=13, 15-0.032 ± 0.43590.574 ± 2.0355
Triglycerides, Follow-up, n=9, 110.637 ± 1.40450.181 ± 0.7767
Urea, Week 8, n=174, 183-0.068 ± 1.32820.015 ± 1.1723
Urea, Taper, n=12, 160.517 ± 0.9249-0.269 ± 1.0223
Urea, Follow-up, n=8, 110.687 ± 0.6998-0.419 ± 1.0801
SecondaryChange From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Picograms
Change From Baseline in Mean Corpuscle Hemoglobin (MCH) at the Indicated Time Points
PicogramsBupropion XLEscitalopram
MCH, Week 8, n=176, 183-0.032 ± 0.74310.049 ± 0.7052
MCH, Taper, n=13, 160.269 ± 0.79410.262 ± 0.7571
MCH, Follow-up, n=10, 8-0.050 ± 1.1909-0.250 ± 0.4598
SecondaryChange From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · Femtoliter
Change From Baseline in Mean Corpuscle Volume (MCV) at the Indicated Time Points
FemtoliterBupropion XLEscitalopram
MCV, Week 8, n=176, 1834.668 ± 62.5158-0.090 ± 2.4759
MCV, Taper, n=13, 160.508 ± 2.22910.181 ± 2.1201
MCV, Follow-up, n=10, 80.320 ± 3.35650.287 ± 1.1205
SecondaryChange From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points

Blood samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Baseline was considered as the value obtained at Screening. Change from Baseline was calculated by subtracting the Baseline value from the specific post-Baseline values. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Mean · 10^12 cells per liter
Change From Baseline in Red Blood Cell (RBC) Count at the Indicated Time Points
10^12 cells per literBupropion XLEscitalopram
RBC Count, Week 8, n=176, 183-0.009 ± 0.2711-0.049 ± 0.2563
RBC Count, Taper, n=13, 16-0.088 ± 0.1599-0.007 ± 0.2560
RBC Count, Follow-up, n=10, 8-0.132 ± 0.40180.036 ± 0.1859
SecondaryNumber of Participants With Urinalysis Data Outside the Normal Range

Urine samples were collected at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). Number of participants with urine specific gravity and potential of hydrogen (pH) outside (higher or lower) the normal range are presented. Only those participants with data available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Week 10
Reported as:
Number · Participants
Number of Participants With Urinalysis Data Outside the Normal Range
ParticipantsBupropion XLEscitalopram
Urine specific gravity, high,Screening, n=265, 2552012
Urine specific gravity, low,Screening, n=265, 25511
Urine specific gravity,high, Week 8, n=171, 17397
Urine specific gravity,low, Week 8, n=171, 17301
Urine specific gravity, high, Taper, n=18, 2800
Urine specific gravity, low, Taper, n=18, 2801
Urine specific gravity, high, Follow-up, n=7, 1403
Urine specific gravity, low, Follow-up, n=7, 1400
Urine pH, high, Screening, n=265, 266718
Urine pH, low, Screening, n=265, 2663728
Urine pH, high, Week 8, n=172, 17859
Urine pH, low, Week 8, n=172, 1782320
Urine pH, high, Taper, n=18, 2801
Urine pH, low, Taper, n=18, 2822
Urine pH, high, Follow-up, n=7, 1400
Urine pH, low, Follow-up, n=7, 1422
SecondaryNumber of Participants With Vital Sign Parameters Outside the Clinical Concern Range

Vital signs including systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR) were taken at Screening (within 14 days prior to dosing), randomization visit (Week 0) and at Weeks 1, 2, 4, 6, 8, Taper visit (Week 9) and Follow-up visit (Week 10). SBP \<30 or \>170 millimeter of mercury (mmHg); DBP \<20 or \>110 mmHg and heart rate \<40 or \>120 beats per minute (bpm) were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with vital signs outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.

Time frame:
Up to Week 10
Reported as:
Number · Participants
Number of Participants With Vital Sign Parameters Outside the Clinical Concern Range
ParticipantsBupropion XLEscitalopram
SBP, high, Any visit post-Baseline10
SBP, low,Any visit post-Baseline00
DBP, high, Any visit post-Baseline00
DBP, low, Any visit post-Baseline00
HR, high, Any visit post-Baseline01
HR, low, Any visit post-Baseline00
SecondaryNumber of Participants With Electrocardiogram (ECG) Data Outside the Clinical Concern Range

ECG was recorded at Screening (within 14 days prior to dosing) and at Week 8, Taper visit (Week 9) and Follow-up visit (Week 10). PR interval \<110 or \>220 millisecond (msec); QRS interval \<60 or \>120 msec and corrected QT (QTc) interval \>450 msec were considered as values outside of clinical concern range and were presented as 'High' or 'Low' values. Number of participants with ECG data outside of clinical concern range at any post-Baseline visit are presented. Only those participants with data available at the specified time points were analyzed.

Time frame:
Up to Week 10
Reported as:
Number · Participants
Number of Participants With Electrocardiogram (ECG) Data Outside the Clinical Concern Range
ParticipantsBupropion XLEscitalopram
PR interval, high, Any visit post-randomization00
PR interval, low,Any visit post-randomization52
QRS interval, high, Any visit post-randomization23
QRS interval, low, Any visit post-randomization01
QTc interval, high, Any visit post-randomization13
QTc interval, low, Any visit post-randomization00
SecondaryChange From Baseline in Changes in Sexual Function Questionnaire (CSFQ)

CSFQ is a questionnaire about sexual activity and sexual function (sexual intercourse, masturbation, sexual fantasies and other activity). CSFQ is a gender-specific questionnaire. Both male and female versions consist of 14 items, each with 5 possible answers. CSFQ has a score in a range of 14 to 70. Higher score indicates higher sexual activity and sexual function. Value at Day 0 (Week 0) was considered as Baseline value. Change from Baseline at Week 8 was calculated by subtracting the Baseline score from the specific post-Baseline score. Only those participants with data available at the specified time points were analyzed.

Time frame:
Baseline (Day 0) and Week 8
Reported as:
Mean · Scores on a scale
Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ)
Scores on a scaleBupropion XLEscitalopram
Change From Baseline in Changes in Sexual Function Questionnaire (CSFQ)3.0 ± 6.470.9 ± 7.21
SecondaryNumber of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS is an assessment tool that evaluates suicidal ideation and behavior. It consists of 10 items, each with two possible answers (yes/no). Suicidal ideation was interpreted if "yes" answer at any time during treatment to any one of the five suicidal ideation questions (item 1-5) on the C-SSRS. Suicidal behavior was interpreted if a "yes" answer at any time during treatment to any one of the five suicidal behavior questions (item 6-10) on the C-SSRS. Suicidal ideation or behavior is interpreted if a "yes" answer at any time during treatment to any one of the ten suicidal ideation and behavior questions (item 1-10) on the C-SSRS. Number of participants with at least one on-treatment C-SSRS assessment were analyzed. Only those participants with data available at the specified time points were analyzed.

Time frame:
Baseline and up to Taper visit (Week 9)
Reported as:
Number · Participants
Number of Participants With Suicidal Ideation or Behavior During Treatment Assessed by Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsBupropion XLEscitalopram
Suicidal Ideation or Behavior5043
Suicidal Ideation5043
Suicidal Behavior21
Self-Injurious Behavior, no suicidal attempt11

Adverse events

Collected over Adverse events (AEs) were collected from the start of study treatment and until the end safety follow-up visit (up to Week 10). SAEs were recorded from the time the consent form is signed until the follow-up visit (up to Week 10).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupropion XL1/266 (0.4%)10/266 (3.8%)151/266 (56.8%)
Escitalopram0/268 (0%)11/268 (4.1%)150/268 (56%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventBupropion XLEscitalopram
DepressionPsychiatric disorders2/2664/268
Depression suicidalPsychiatric disorders1/2660/268
Lacrimal structure injuryInjury, poisoning and procedural complications1/2660/268
OverdoseInjury, poisoning and procedural complications1/2660/268
Somatic symptom disorderPsychiatric disorders1/2660/268
TinnitusEar and labyrinth disorders1/2660/268
ConjunctivitisInfections and infestations1/2660/268
Suicide attemptPsychiatric disorders1/2660/268
UrticariaSkin and subcutaneous tissue disorders1/2660/268
Blood pressure increasedInvestigations0/2661/268
Most frequent other events
Showing 10 of 166
Most frequent other events
EventBupropion XLEscitalopram
NauseaGastrointestinal disorders28/26650/268
DizzinessNervous system disorders25/26623/268
HeadacheNervous system disorders20/26615/268
Dry mouthGastrointestinal disorders16/26615/268
Viral upper respiratory tract infectionInfections and infestations15/26613/268
Decreased appetiteMetabolism and nutrition disorders11/26615/268
ConstipationGastrointestinal disorders14/2669/268
SomnolenceNervous system disorders1/26613/268
PalpitationsCardiac disorders11/2665/268
Abdominal discomfortGastrointestinal disorders9/2669/268

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Bupropion XLEscitalopramTotal
Mean36.9 ± 11.9237.6 ± 12.0937.3 ± 12.00
Sex: Female, Male
Sex: Female, Male(Participants)Bupropion XLEscitalopramTotal
Female168172340
Male9896194
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Bupropion XLEscitalopramTotal
Asian - East Asian Heritage266268534
08

Study locations

20 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510180, China
  • GSK Investigational Site
    Nanning, Guangxi 530021, China
  • GSK Investigational Site
    Guiyang, Guizhou 550004, China
  • GSK Investigational Site
    Baoding, Hebei 071000, China
  • GSK Investigational Site
    Harbin, Heilongjiang 150070, China
  • GSK Investigational Site
    Changsha, Henan 410011, China
  • GSK Investigational Site
    Changsha, Hunan, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210029, China
  • GSK Investigational Site
    Xian, Shaanxi 710032, China
  • GSK Investigational Site
    Taiyuan, Shanxi, China
  • GSK Investigational Site
    Xi'an, Shanxi, China
  • GSK Investigational Site
    Kunming, Yunnan 650032, China
  • GSK Investigational Site
    Hangzhou, Zhejiang 310003, China
  • GSK Investigational Site
    Beijing, 100083, China
  • GSK Investigational Site
    Beijing, 100088, China
  • GSK Investigational Site
    Beijing, 100096, China
  • GSK Investigational Site
    Guangzhou, 510370, China
  • GSK Investigational Site
    Shanghai, 200030, China
  • GSK Investigational Site
    Shanghai, 200065, China
  • GSK Investigational Site
    Wuhan, China
09

References and documents

Publications

  • Shen Y, Zhao Q, Yu Y, Tan Y, Zhang H, Xu X, Wang Z, Li Y, Hu J, Zhong J, Li H. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. J Affect Disord. 2019 Oct 1;257:143-149. doi: 10.1016/j.jad.2019.07.023. Epub 2019 Jul 5. PubMed 31301615 ↗

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Oct 2016, 20 months.

Results were first posted in Feb 2019, 2 years 4 months after primary completion.

Of 95 industry-sponsored phase 3 interventional studies under Depressive Disorder, Major, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 20 months is below that.

Counting every sponsor, half of 124 studies reached it within 27 months; a quarter within 21 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2014
First posted
Jul 16, 2014
StartActual
Feb 10, 2015
Primary completionActual
Oct 10, 2016
CompletionActual
Oct 25, 2016
Results first posted
Feb 18, 2019
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02191397
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 16, 2014
Start date
Feb 10, 2015
Primary completion
Oct 10, 2016
Completion
Oct 25, 2016
Results posted
Feb 18, 2019
Last update
Feb 25, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupropion

Start the discussion